Literature DB >> 24599695

Concordance between criteria for covariate model building.

Stefanie Hennig1, Mats O Karlsson.   

Abstract

When performing a population pharmacokinetic modelling analysis covariates are often added to the model. Such additions are often justified by improved goodness of fit and/or decreased in unexplained (random) parameter variability. Increased goodness of fit is most commonly measured by the decrease in the objective function value. Parameter variability can be defined as the sum of unexplained (random) and explained (predictable) variability. Increase in magnitude of explained parameter variability could be another possible criterion for judging improvement in the model. The agreement between these three criteria in diagnosing covariate-parameter relationships of different strengths and nature using stochastic simulations and estimations as well as assessing covariate-parameter relationships in four previously published real data examples were explored. Total estimated parameter variability was found to vary with the number of covariates introduced on the parameter. In the simulated examples and two real examples, the parameter variability increased with increasing number of included covariates. For the other real examples parameter variability decreased or did not change systematically with the addition of covariates. The three criteria were highly correlated, with the decrease in unexplained variability being more closely associated with changes in objective function values than increases in explained parameter variability were. The often used assumption that inclusion of covariates in models only shifts unexplained parameter variability to explained parameter variability appears not to be true, which may have implications for modelling decisions.

Mesh:

Substances:

Year:  2014        PMID: 24599695     DOI: 10.1007/s10928-014-9350-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  19 in total

1.  Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; Alison H Thomson; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

2.  A reduction in between subject variability is not mandatory for selecting a new covariate.

Authors:  Chakradhar V Lagishetty; Pavan Vajjah; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-06       Impact factor: 2.745

3.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

4.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

5.  A fast method for testing covariates in population PK/PD Models.

Authors:  Akash Khandelwal; Kajsa Harling; E Niclas Jonsson; Andrew C Hooker; Mats O Karlsson
Journal:  AAPS J       Date:  2011-07-02       Impact factor: 4.009

6.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

7.  Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.

Authors:  Ahmed F Hawwa; Paul S Collier; Jeff S Millership; Anthony McCarthy; Sid Dempsey; Carole Cairns; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

8.  Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.

Authors:  Beesan Tan; Himanshu Naik; In-Jin Jang; Kyung-Sang Yu; Lee E Kirsch; Chang-Sik Shin; J Carl Craft; Lawrence Fleckenstein
Journal:  Malar J       Date:  2009-12-18       Impact factor: 2.979

9.  Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.

Authors:  R Bruno; M C Iliadis; B Lacarelle; V Cosson; J W Mandema; Y Le Roux; G Montay; A Durand; M Ballereau; M Alasia
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

10.  Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.

Authors:  M Sandström; H Lindman; P Nygren; M Johansson; J Bergh; M O Karlsson
Journal:  Cancer Chemother Pharmacol       Date:  2006-02-08       Impact factor: 3.333

View more
  4 in total

1.  A Population Pharmacokinetic Model of Gentamicin in Pediatric Oncology Patients To Facilitate Personalized Dosing.

Authors:  C C Llanos-Paez; C E Staatz; R Lawson; S Hennig
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  Differences in the Pharmacokinetics of Gentamicin between Oncology and Nononcology Pediatric Patients.

Authors:  C C Llanos-Paez; C E Staatz; R Lawson; S Hennig
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

3.  Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.

Authors:  Celeste Bloomfield; Christine E Staatz; Sean Unwin; Stefanie Hennig
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

4.  An introduction to the full random effects model.

Authors:  Gunnar Yngman; Henrik Bjugård Nyberg; Joakim Nyberg; E Niclas Jonsson; Mats O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-01-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.